An investigation of the effect of the various complement geneotype and phenotype in the outcome of ranibizumab treatment in patients of age related mascular degeneration (AMD).

Trial Profile

An investigation of the effect of the various complement geneotype and phenotype in the outcome of ranibizumab treatment in patients of age related mascular degeneration (AMD).

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2015 Status changed from completed to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 12 Nov 2015 Status changed from recruiting to completed, as reported by United Kingdom Clinical Research Network record.
    • 04 Sep 2015 Accrual to date is 77% as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top